Gossamer bio is celebrating a phase 2 win after a series of fails, but analysts aren't popping the champagne just yet.

Autolus Therapeutics is almost ready to make a late play for the CD19 CAR-T cell therapy space. The biotech now has phase 2 data showing its asset hit the primary endpoint at an interim analysis and is setting out plans for further data to file for FDA approval next year and try to join Bristol Myers Squibb, Gilead and Novartis on the market.

In a statement that calls the results “implausible” four times, and “unplausible” once, Relmada made the case that its RELIANCE I study was undone by data from two high-enrolling sites.

Prometheus Biosciences has laid down a major marker in the anti-TL1A space. Days after Pfizer offloaded its rival candidate to Roivant, Prometheus has reported midphase data in ulcerative colitis and Crohn’s disease that sent its stock up 170% in premarket trading.

Neurocrine Biosciences’ $45 million rare pediatric epilepsy bet has fallen at an early clinical hurdle. Thirty months after licensing the selective T-type calcium channel inhibitor, the biotech has reported its second setback in quick succession with the failure to beat placebo in a small phase 2 clinical trial.

SPAC deals are creeping back into the mainstream, with Liminatus Pharma and Iris Acquisition Corp. becoming the latest in the biotech sphere to test the waters.

Four months after laying off a chunk of its staff, X4 Pharmaceuticals has some good news to share, as the biotech’s WHIM syndrome therapy improved white blood cell counts in patients during a phase 3 trial.

The FDA has pumped the brakes on PTC Therapeutics’ Huntington's disease trial in the U.S. even as the studies kick into gear in other countries.

Days after PureTech confirmed speculation of a merger with Nektar, conversations between the two companies have ceased, for now. PureTech says its original statement created the impression that the talks were farther along than they were.

CinCor Pharma is clinging to subgroup analysis despite its mid-stage hypertension study missing its primary endpoint in hopes of advancing the candidate to a phase 3 trial. Investors seemed less convinced, sending CinCor’s shares plummeting 43% in the opening minutes of trading on Monday to $14.80 from a Friday close of $26.53.